Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931667 · ClinicalTrials.gov registry record · Phase 3
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis
A Phase 3 study, sponsored by Biosplice Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT04931667 is a Phase 3 study that was terminated before completion, run by Biosplice Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT04931667, a Phase 3 study, was terminated before completion, sponsored by Biosplice Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.
Interventions
- DRUG Lorecivivint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04931667
The ClinicalTrials.gov registry entry for NCT04931667 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lorecivivint is the first listed.
NCT04931667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04931667 about?
NCT04931667 is a clinical study titled "3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis". This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.
What is the current status of trial NCT04931667?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2021-07-15. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT04931667?
The interventions under investigation include: Lorecivivint (DRUG).
Who is sponsoring clinical trial NCT04931667?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.